Patient with congenital factor VII deficiency undergoing brain tumor neurosurgery successfully treated with recombinant factor VIIa and fresh frozen plasma: A case report and literature review
Chaoyu Huang,Yongjia Yu,Ningneng Zhai,Wuning Mo,Faquan Lin
DOI: https://doi.org/10.1097/md.0000000000036694
IF: 1.6
2024-01-10
Medicine
Abstract:Congenital factor VII deficiency (FVIID), caused by mutations in the F7 gene, is a rare autosomal recessive blood disorder with an estimated prevalence of 1:500,000. [ 1–3 ] FVIID can cause spontaneous bleeding, including menorrhagia, ecchymosis, epistaxis, gum bleeding, hematuria, gastrointestinal bleeding, hemarthrosis, and intracranial hemorrhage. [ 4 ] Unlike hemophilia, factor VII activity (FVII:C) does not serve as a predictor of hemorrhage severity. [ 5 ] The primary therapeutic option is replacement therapy (RT), which includes recombinant activated factor VII (rFVIIa), fresh frozen plasma (FFP), plasma-derived factor VII, and prothrombin complex concentrates. [ 6 ] Furthermore, 40% to 70% of patients remain asymptomatic, [ 4 , 7 , 8 ] for whom surgery is considered a major threat. [ 9 ] Most of them are occasionally diagnosed by a prolonged prothrombin time (PT) and a decreased FVII:C in preoperative coagulation tests. [ 10 ] Despite the absence of previous bleeding episodes, the inherent hemostatic defect is consistently a predisposition to excessive bleeding. In patients with coagulation factor deficiency, the prevention of surgical bleeding should be meticulously considered. [ 11 ] However, effective guidelines for the perioperative coagulation management of patients with FVIID have yet to be established, and consensus on the optimal strategy for rFVIIa infusion remains elusive. [ 12 ] Currently, the perioperative management of patients with FVIID are individualized, considering factors such as hemorrhage history, family history, FVII:C baseline, and the specific type of surgery. [ 10 ]
medicine, general & internal